Twice-Yearly HIV Prevention Drug Remains Scarce in UgandaHIV Prevention Breakthrough Is Out of Reach for Those Who Need ItGeneric HIV Prevention Drug Offers Path to Wider Access
On November 3, access to long-acting HIV-prevention drug lenacapavir remained limited in Mbarara, Uganda, despite high demand. A tentatively approved generic could expand supplies to 120 low-income countries.On November 3, people in Mbarara, Uganda, were still struggling to obtain lenacapavir, a twice-yearly HIV-prevention drug. A proposed generic expansion has not yet answered calls for faster, broader access.On November 3, lenacapavir remained scarce in Mbarara, Uganda, while a tentatively approved generic could bring the drug to 120 low-income countries at about $40 a year.